Fact-checked by Grok 2 weeks ago

Invitae

Invitae is an American medical genetics company founded in 2010 and headquartered in San Francisco, California, that specializes in providing comprehensive genetic testing services to deliver actionable insights for patient care across various hereditary conditions.^[1] The company focuses on next-generation sequencing-based tests, offering a broad portfolio including panels for oncology, cardiology, neurology, immunology, and reproductive health, designed to support diagnosis, risk assessment, and personalized treatment decisions.^[2] With an emphasis on accessibility, Invitae has historically aimed to make high-quality genetic information affordable and integrated into mainstream medical practice, processing DNA samples from clinical and at-home kits to inform healthcare providers and patients.^[3] In its early years, Invitae rapidly expanded its test catalog and partnerships, going public in 2015 and acquiring complementary technologies to build one of the largest genetic databases in the industry.^[4] By 2023, it had grown to serve approximately 20,000 healthcare providers and tested about 1 million patients that year, with a cumulative total exceeding 4 million patients, leveraging advanced machine learning through its Invitae Generation™ platform to enhance result interpretation and clinical utility.^[5]^[6]^[7] However, facing mounting financial pressures from high operational costs and reimbursement challenges in the genetic testing sector, Invitae filed for Chapter 11 bankruptcy protection on February 13, 2024.^[8] The bankruptcy proceedings culminated in an asset sale approved by the court in May 2024, with Labcorp acquiring substantially all of Invitae's assets for $239 million in cash, completing the transaction in August 2024 on a going-concern basis.^[9] This integration has preserved Invitae's testing capabilities within Labcorp's extensive laboratory network, expanding access through in-network coverage with major U.S. health plans and over 2,000 patient service centers for sample collection.^[10] As of 2025, Invitae operates collaboratively with Labcorp, continuing to advance genetic testing for conditions like hereditary cancers, cardiovascular diseases, and rare disorders while supporting clinical trials and proactive health strategies, including expansions like integration with electronic health record systems.^[11]^[12]

History

Founding and early development

Invitae was founded on January 13, 2010, as Locus Development, Inc., a Delaware corporation focused on developing comprehensive genetic diagnostics to aggregate and streamline multiple genetic tests into accessible clinical services.^[3] In February 2012, Genomic Health, Inc., a precision oncology company, announced the formation of a new wholly owned subsidiary dedicated to clinical genetics, which combined with Locus Development later that year to form Invitae Corporation as an independent entity.^[13] This spin-off allowed Invitae to operate autonomously, with Genomic Health retaining a significant equity stake and providing initial operational support to advance the integration of genetic testing into mainstream medicine.^[14] From its inception, Invitae's mission centered on bringing comprehensive genetic information into routine medical practice to enhance the quality of healthcare for billions of people by making advanced diagnostics more affordable, rapid, and clinically actionable.^[3] Early development emphasized building a proprietary platform for high-throughput genetic analysis, including automation and bioinformatics tools to interpret complex genomic data efficiently. The company secured initial funding through investments tied to the spin-off, including commitments from Genomic Health exceeding $20 million across seed and early rounds to support laboratory development and regulatory compliance.^[15] Invitae went public on February 12, 2015, with an initial public offering on the New York Stock Exchange under the ticker symbol NVTA, raising approximately $101.6 million in gross proceeds from the sale of 6.35 million shares at $16 per share, with an overallotment option bringing total proceeds to $116.8 million.^[16] These funds were allocated to expand testing capabilities, scale operations, and accelerate commercialization efforts. In late November 2013, Invitae launched its first commercial genetic testing service, a comprehensive panel analyzing 216 genes associated with 85 hereditary disorders, priced at a flat rate of $1,500 to promote broader adoption in clinical settings.^[3]

Expansion and growth

Following its initial public offering in 2015, Invitae experienced significant operational scaling, with billable test volumes growing from approximately 19,000 in 2015 to 57,000 in 2016, reflecting more than 200% year-over-year increase driven by expanded test offerings and payer coverage.^[17]^[18] By 2017, volumes reached about 145,000 billable tests, a more than 150% rise from the prior year, supported by broader adoption in clinical settings for hereditary conditions.^[19] This momentum continued, with sample accessions surpassing 303,000 in 2018 and climbing to 482,000 in 2019, marking over 59% growth and establishing Invitae as a leader in high-volume genetic testing.^[20]^[21] Invitae began expanding into international markets around 2017, establishing subsidiaries in regions including Europe (Netherlands) and Asia-Pacific (Australia), alongside Canada and Israel, to facilitate direct sales and distribution of its tests abroad.^[19] This included limited partnerships with international distributors for logistics and support, contributing to non-U.S. revenue of about $14.3 million in 2019, or roughly 6% of total revenue, primarily from Canada and other global markets.^[19] The company's global growth strategy emphasized compliance with foreign regulations and increasing sales personnel outside the U.S. to penetrate new healthcare systems.^[19] To support this scaling, Invitae developed in-house, CLIA-certified laboratories, with its primary facility in San Francisco serving as the headquarters and main production site following a 2015 lease expansion to 103,000 square feet for enhanced DNA testing capacity.^[22]^[23] An additional CLIA-certified lab in Irvine, California, was established to bolster operations, enabling redundant processing and handling of growing test demands without reliance on external vendors.^[19] Key milestones underscored this period of growth, including the March 2017 launch of whole-exome sequencing services, which used next-generation sequencing to analyze up to 20,000 genes for complex cases, broadening Invitae's diagnostic reach.^[24] By the end of 2019, Invitae had cumulatively processed more than 1 million patient tests since its inception, with over 750,000 delivered in the prior two years alone, highlighting its maturation into a high-throughput genetics provider.^[25] Employee numbers expanded substantially to meet operational needs, rising from around 161 in early 2015 to approximately 800 by 2018 and 1,300 by 2019, with particular emphasis on hiring in bioinformatics for data analysis and genetic counseling to support test interpretation and patient guidance.^[3]^[19] This workforce growth enabled Invitae to handle increased volumes while maintaining quality standards. Acquisitions during this era further accelerated expansion by integrating complementary technologies and expertise.^[19]

Key acquisitions

Invitae pursued several strategic acquisitions to broaden its genetic testing capabilities, particularly in reproductive health, oncology, and patient data management. In 2017, the company expanded into reproductive and pediatric diagnostics through two key purchases. It acquired Good Start Genetics, a provider of carrier screening and preimplantation genetic testing using next-generation sequencing technologies like GeneVu and EmbryVu, for approximately $18.3 million in cash to cover debt, up to 1.65 million shares of Invitae stock, and assumption of $6 million in liabilities.^[26] This move enhanced Invitae's offerings in reproductive carrier screening to support family planning and IVF processes. Complementing this, Invitae completed the acquisition of CombiMatrix in November 2017 for an enterprise value of $34.9 million, issuing about 2.7 million shares valued at $21.2 million and accounting for 1.7 million shares related to warrants.^[27] CombiMatrix brought expertise in prenatal diagnosis, miscarriage analysis, and pediatric disorders via its CombiSNP Array chromosomal microarray technology, integrating cytogenomic testing with Invitae's platform to cover the full spectrum of reproductive health stages.^[26] Building on this foundation, Invitae targeted oncology advancements with the acquisition of ArcherDX. Announced in June 2020 and completed in October 2020, the deal valued ArcherDX at up to $1.4 billion, with upfront payment of $325 million in cash and 30 million shares of Invitae stock, plus potential additional 27 million shares tied to milestones.^[28]^[29] The strategic intent was to merge Invitae's germline testing with ArcherDX's Anchored Multiplex PCR technology for somatic and RNA-based assays, enabling comprehensive cancer profiling, liquid biopsies, and personalized monitoring to optimize therapies in precision oncology.^[28] In 2021, Invitae further integrated clinical data capabilities by acquiring Ciitizen for approximately $325 million, consisting of $125 million in cash and about 7.07 million shares of Invitae stock, plus up to $225 million in restricted stock units for employees.^[30] Announced in September 2021, this acquisition incorporated Ciitizen's AI-driven platform for aggregating and organizing patient medical records, particularly for cancer patients, to facilitate clinical trial matching, outcome improvement, and research acceleration by combining genomic and consented health data.^[30] These acquisitions significantly expanded Invitae's test portfolio to over 2,500 offerings by 2021, enabling a more integrated approach to genetic information services across reproductive, oncology, and data-driven care. However, the aggressive expansion, including 13 deals between 2019 and 2021, substantially increased Invitae's debt load by about $1.5 billion, straining finances amid rising interest rates and operational costs.^[31]

Bankruptcy and dissolution

Invitae's aggressive expansion strategy, including prior acquisitions, led to mounting financial losses and a significant debt burden. In 2022, the company generated $516 million in revenue but reported a net loss of $3.1 billion, driven by high operational costs and investments in scaling genetic testing services.^[32]^[5] These challenges culminated in Invitae filing for voluntary Chapter 11 bankruptcy protection on February 13, 2024, in the U.S. Bankruptcy Court for the District of New Jersey, with estimated liabilities of $1.6 billion and assets of $535 million.^[33]^[8] The filing was precipitated by escalating costs associated with genetic testing operations and persistent difficulties in obtaining sufficient reimbursements from insurers and healthcare providers.^[34]^[35] As part of the bankruptcy proceedings, Invitae pursued the sale of its assets to address its debts. In January 2024, the company completed the sale of its reproductive health assets, including carrier screening and non-invasive prenatal testing capabilities, to Natera for an upfront payment of $10 million plus up to $42.5 million in milestone payments, totaling a potential value of $52.5 million.^[36]^[37] Subsequently, in May 2024, the bankruptcy court approved the sale of Invitae's core genetic testing assets to Labcorp for $239 million, enabling the integration of these tests into Labcorp's broader diagnostics portfolio.^[38]^[39] The bankruptcy process marked the end of Invitae's operations as an independent entity by mid-2024, following the asset sales and court confirmation of the reorganization plan in August 2024.^[40] The transaction with Labcorp was completed on August 5, 2024, on a going-concern basis, preserving Invitae's testing capabilities within Labcorp's network. As of 2025, Invitae genetic tests continue to be offered collaboratively through Labcorp, with expansions such as integration with Epic Aura for streamlined ordering and results delivery.^[12] This wind-down involved substantial layoffs, affecting more than 1,500 employees across multiple restructuring rounds in 2022 through 2024.^[41]^[42]

Products and services

Genetic testing panels

Invitae's genetic testing panels primarily consist of multi-gene assays designed to identify inherited variants associated with hereditary conditions across various medical specialties. The company's comprehensive offerings include panels such as the Invitae Genetic Health Screen, which analyzes 167 genes linked to hereditary cancers (including BRCA1 and BRCA2 for breast and ovarian cancer risk), cardiovascular disorders (such as genes for cardiomyopathies like MYH7 and TTN), and neurological conditions (encompassing genes for disorders like epilepsy and neuropathies, e.g., SCN1A).^[43] These panels enable targeted sequencing of clinically relevant genes, facilitating the detection of pathogenic variants that inform personalized medical management. Following the 2024 acquisition by Labcorp, Invitae's portfolio covers tests for over 4,700 inherited conditions as of 2024, emphasizing actionable insights for common and rare diseases.^[44] In addition to targeted panels, Invitae introduced whole exome sequencing in 2017, which examines approximately 20,000 protein-coding genes to diagnose rare and undiagnosed disorders when standard panels yield inconclusive results.^[45] This approach analyzes thousands of genes simultaneously, providing broader coverage for complex cases involving novel or multiple variants. Whole genome sequencing options were later developed through partnerships, such as with Pacific Biosciences in 2021, to enhance resolution for structural variants and non-coding regions in rare disorder diagnostics.^[46] These sequencing services support clinical applications in neurology, cardiology, and oncology, where identifying elusive genetic causes can guide therapeutic decisions. To improve accessibility, Invitae implemented sponsored testing programs starting in 2018, partnering with biopharmaceutical companies to offer no-cost genetic testing and counseling for eligible patients meeting specific clinical criteria, such as those suspected of hereditary cancers or cardiomyopathies.^[47] These programs remove financial barriers, enabling broader adoption for risk assessment, confirmatory diagnosis, and family planning. For instance, panels aid in cascade testing for at-risk relatives, potentially preventing disease onset through early interventions like enhanced screening or prophylactic measures.^[48] The clinical utility of these panels lies in their role for proactive health management, with results integrated into electronic health records (EHRs) via partnerships like the 2023 agreement with Epic Systems.^[49] This integration allows providers seamless access to genetic data within patient charts, supporting informed decision-making in routine care. Overall, Invitae's panels have been instrumental in identifying hereditary risks, with applications spanning diagnosis of over 4,700 conditions as of 2024 and enhancing outcomes through evidence-based genetic insights.^[44]

Specialized programs and technologies

Invitae developed specialized programs and technologies to address niche areas in genetic testing, particularly in reproductive health, pediatrics, cardiology, oncology, and population screening, often integrating capabilities from strategic acquisitions. These offerings emphasized accessible, targeted diagnostics to support clinical decision-making in high-impact scenarios. Following the 2024 acquisition by Labcorp, these services continue to be available through Labcorp's network, with updates to billing and patient programs as of 2025.^[50] The CombiSNP Array, integrated following the 2017 acquisition of CombiMatrix, is a microarray technology designed for detecting copy number variations and other chromosomal abnormalities in prenatal and postnatal samples.^[27] This SNP-based platform features over 850,000 probes with high-resolution coverage in gene-rich regions, enabling identification of microdeletions, duplications, and aneuploidies that may contribute to developmental disorders or miscarriage risks.^[51] In reproductive health, Invitae expanded its services to include comprehensive carrier screening and non-invasive prenatal testing (NIPT) panels, which assess risks for inherited disorders and fetal chromosomal conditions as early as 10 weeks gestation.^[52] Carrier screening evaluates hundreds of genes associated with conditions like cystic fibrosis and spinal muscular atrophy, providing couples with information on potential recessive trait inheritance, while NIPT uses cell-free fetal DNA to screen for trisomies and sex chromosome aneuploidies with high sensitivity.^[53] The Invitae Detect Program, launched in 2019, offered no-cost genetic testing and counseling for cardiomyopathies and arrhythmias to individuals suspected of familial forms and their at-risk relatives.^[48] This initiative targeted genes linked to conditions such as hypertrophic cardiomyopathy and long QT syndrome, aiming to facilitate early diagnosis, family cascade screening, and personalized management to reduce sudden cardiac events.^[54] Integration of ArcherDX technologies in 2020 enhanced Invitae's oncology capabilities through RNA sequencing assays for tumor profiling and minimal residual disease monitoring.^[29] These assays, including FusionPlex panels, detect gene fusions and expression changes in solid tumors, supporting targeted therapy selection and surveillance of treatment response by analyzing RNA from tumor tissue or liquid biopsies.^[28] The eMERGE Panel, a 59-gene test developed in collaboration with the Electronic Medical Records and Genomics (eMERGE) network, focused on population health screening for common adult-onset conditions like hypercholesterolemia, hereditary cancers, and pharmacogenomic risks.^[55] This panel prioritized actionable variants that could inform preventive care and medication adjustments, integrating electronic health records with genetic insights to promote scalable, proactive interventions.^[56]

Corporate affairs

Leadership and governance

Invitae Corporation's leadership underwent significant transitions during its periods of expansion and financial challenges. Sean George, a co-founder of the company, served as Chief Executive Officer from January 2017 until July 2022, bringing prior experience in biotechnology from roles such as Vice President of Labeling and Detection/Dx Solutions at Invitrogen, where he contributed to molecular diagnostics advancements following the acquisition of Molecular Probes. Upon stepping down as CEO, George transitioned to a consulting role briefly before continuing as a member of the Board of Directors, providing ongoing strategic input during the company's restructuring efforts.^[57]^[58]^[59] In July 2022, Kenneth D. Knight, who had joined as Chief Operating Officer in mid-2020, was appointed CEO, succeeding George and also joining the board. Knight's tenure, which extended through 2023 and into the company's bankruptcy proceedings in 2024, emphasized operational efficiencies and cost reductions to address ongoing financial losses amid a challenging market for genetic testing services. To support restructuring efforts, Invitae appointed David Sholehvar as Chief Operating Officer in October 2023, leveraging his healthcare leadership experience, and Ana Schrank as Chief Financial Officer in September 2023, effective October 2, drawing on her finance expertise from prior roles in biotech and investment.^[59]^[60]^[61]^[62] The board of directors, composed of experienced professionals in biotechnology and healthcare, played a key role in governance, particularly during the crisis period leading to bankruptcy. Following the 2022 leadership shift, Randy Scott, a biotech veteran and former chairman from 2017 to 2019, returned as chairman, while Eric Aguiar served as lead independent director; the board included other industry experts such as Chitra Nayak and William H. Osborne, appointed in 2023, ensuring oversight of strategic decisions and compliance amid financial distress. In its 2023 Environmental, Social, and Governance report, Invitae highlighted a commitment to diverse leadership, with the executive team comprising 40% women (4 out of 10 members) and the board achieving 50% female representation.^[63]^[64]^[65]^[66] Following the asset sale to Labcorp in August 2024, Invitae's board of directors was dissolved and its officers, including CEO Kenneth D. Knight and CFO Ana Schrank, ceased their roles as part of the bankruptcy plan confirmation, with the team and operations integrated into Labcorp.^[67]

Financial overview

Invitae raised over $200 million in venture funding prior to its initial public offering (IPO) in 2015.^[68] In 2020, the company completed a major acquisition of ArcherDX, valued at up to $1.4 billion and primarily structured as an exchange of Invitae stock.^[69] The company's revenue demonstrated significant growth in its early public years, increasing from $25 million in 2016 to $516.3 million in 2022, largely propelled by rising test volumes and expanded market penetration.^[70] This expansion reflected Invitae's scaling of genetic testing services amid growing demand for personalized medicine.^[5] Despite revenue gains, Invitae faced persistent profitability hurdles, with cumulative net losses surpassing $6 billion by the end of 2023, attributed to substantial investments in research and development (R&D) as well as costs associated with acquisitions.^[71] These expenditures supported innovation in genetic testing technologies but strained financial sustainability.^[5] Invitae's stock debuted on the New York Stock Exchange in February 2015 at $16 per share following its IPO.^[72] The shares reached a peak of approximately $57 in late 2020 before declining sharply, culminating in delisting from the NYSE in February 2024 due to sustained low trading prices.^[73]^[74] To enhance accessibility, Invitae adopted a sponsored testing reimbursement model, partnering with biopharma companies to cover costs for eligible patients and thereby reducing out-of-pocket expenses.^[75] While this approach boosted test volumes, it exerted downward pressure on profit margins by limiting revenue per test compared to traditional insurance reimbursements.^[35]

References

[1]
Invitae 2025 Company Profile: Valuation, Investors, Acquisition
Invitae was founded in 2010. Where is Invitae headquartered? Invitae is headquartered in San Francisco, CA. What is the size of Invitae?
[2]
Genetic test catalog - Invitae
Explore Invitae's wide array of panels from our test catalog. Our panels offer actionable genetic insights that can help improve diagnosis and patient care.Invitae Common Hereditary... · Invitae Multi-Cancer Panel · Neurology · Immunology
[3]
Invitae Corporation - SEC.gov
Invitae's mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.
[4]
https://www.bccresearch.com/company-index/profile/invitae-inc
[5]
Medical genetic testing that experts trust – Labcorp Invitae
Our easy-to-order genetic tests help you provide informed care for your patients. Plus, we're an in-network laboratory with most major health plans.Test catalog · Oncology · Cardiology · Papers and presentations
[6]
Genetic test maker Invitae prepares for bankruptcy - WSJ - Reuters
Feb 5, 2024 · Genetic test maker Invitae is preparing to file for bankruptcy within weeks, the Wall Street Journal reported on Monday, according to people ...
[7]
Invitae Receives Court Approval for Sale to Labcorp
May 7, 2024 · Pursuant to the asset purchase agreement, Labcorp will acquire select assets of Invitae on a going concern basis for $239 million in cash ...
[8]
Labcorp Finalizes Acquisition of Select Assets of Invitae
Aug 5, 2024 · The acquisition expands Labcorp's specialty testing capabilities and the company's ability to utilize genetic data to improve clinical trials ...
[9]
Company Formation - Invitae
Feb 6, 2012 · The subsidiary is expected to be established by March 1, 2012 and provide its first commercial service in 2013. The new venture will be led by ...Missing: history 2010
[10]
Spinning out InVitae, Genomic Health Aims to Maintain Core Focus ...
Aug 15, 2012 · Spinning out InVitae, Genomic Health Aims to Maintain Core Focus on Cancer Diagnostics · Get the full story with GenomeWeb Premium.
[11]
Joining Forces with Locus Development - Invitae
Aug 8, 2012 · Genomic Health has committed to make an additional investment of up to $5 million in the combined entity's current Series C financing round, ...
[12]
Invitae Announces Completion of Initial Public Offering and Full ...
Feb 18, 2015 · Total gross proceeds from the offering were approximately $116.8 million , before deducting underwriting discounts and commissions and other ...
[13]
Invitae Announces Full Year 2015 Financial Results and 2016 ...
Feb 9, 2016 · Met volume guidance in 2015 with approximately 19,000 billable tests demonstrating more than 400% year-over-year growth, reduced cost of ...Missing: exact | Show results with:exact
[14]
Invitae meets annual volume guidance, projects doubling of ... - Invitae
Jan 6, 2017 · In addition, Invitae added multiple regional payers in the fourth quarter, bringing the total lives covered to more than 175 million.Missing: count 2019
[15]
[PDF] Invitae Corporation - AnnualReports.com
Feb 28, 2020 · ... $13.5 million for depreciation and amortization, $5.3 million ... share, and 3.5 million shares of our Series A convertible preferred stock ...
[16]
Invitae Corp (NVTA) 10-K Annual Report February 2019 - Last10K
Increased test volume by 102% year-over-year: · Accessioned approximately 303,000 samples in 2018, including approximately 87,000 samples in the fourth quarter, ...
[17]
Invitae Reports $216.8 Million in Annual Revenue Driven by More ...
Feb 19, 2020 · Invitae - Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019.Missing: 2016 | Show results with:2016
[18]
Licensing | Invitae
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory.Missing: house facilities
[19]
Genetic Test Company Invitae Leases Flagship Site in San ...
Sep 23, 2015 · San Francisco-based Invitae Corp. recently leased a 103,000-square-foot building on 16th Street, the former headquarters of retailer Jessica ...Missing: CLIA | Show results with:CLIA
[20]
Invitae announces introduction of exome testing - PR Newswire
Mar 30, 2017 · Invitae's high-quality exome testing uses next-generation sequencing (NGS) technology to analyze the coding regions, called exons, of up to ...
[21]
Invitae preliminary 2019 financial results demonstrate strong ...
Jan 12, 2020 · Invitae has now provided in-depth medical genetic sequencing for more than one million patients since launch, including more than 750,000 in the ...Missing: processed | Show results with:processed
[22]
Invitae Acquiring Good Start Genetics and CombiMatrix, Adding ...
Jul 31, 2017 · Invitae has entered into a definitive agreement to acquire privately held Good Start Genetics, a molecular diagnostics company focused on preimplantation and ...Missing: ArcherDX Citizen
[23]
Invitae Completes Acquisition of CombiMatrix, Becoming a Leader ...
Nov 15, 2017 · The acquisition of CombiMatrix complements Invitae's recent acquisition of another reproductive genetics company, Good Start Genetics, to ...Missing: ArcherDX Citizen
[24]
Invitae and ArcherDX to create a global leader in comprehensive ...
Jun 22, 2020 · Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.Missing: CombiMatrix Citizen
[25]
Invitae Completes Transaction with ArcherDX to Bring ...
Oct 5, 2020 · Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain ...Missing: CombiMatrix Citizen
[26]
Invitae to Acquire Ciitizen to Strengthen its Patient-Consented ...
Sep 7, 2021 · Under the terms of the agreement, Invitae will acquire Ciitizen for approximately $325 million (subject to adjustment), consisting of (i) ...
[27]
Law firm Kirkland conflicted in Invitae bankruptcy, DOJ watchdog says
Apr 16, 2024 · When it filed for bankruptcy, Invitae said it had taken on too much debt to fund its expansion from 2019 to 2021.Invitae made 13 acquisitions ...
[28]
[PDF] Invitae Corporation - SEC.gov
Feb 28, 2023 · Invitae Corporation is a Delaware-based company, with its principal office in San Francisco, California, and its stock symbol is NVTA.
[29]
Invitae Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 28, 2023 · Net loss for the fourth quarter of 2022 was $99.8 million, or a $0.41 net loss per share, compared to net loss of $205.1 million, or net ...
[30]
Invitae files for Chapter 11 bankruptcy - MedTech Dive
Feb 14, 2024 · Invitae also raised nearly $1.2 billion in convertible debt from Softbank in 2021.
[31]
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale ...
Feb 13, 2024 · To ensure the business will operate in the ordinary course during chapter 11, Invitae has sought court approval to fund the case using its cash ...Missing: acquisitions | Show results with:acquisitions
[32]
Genetic test maker Invitae files for bankruptcy protection in US
Feb 14, 2024 · The company said in a court filing that its estimated assets were in the $500 million - $1 billion range, while its liabilities were in the $1 ...
[33]
Unprofitable Genetic Testing Labs – The Size of the Loss, The ...
Sep 26, 2022 · Publicly traded genetic testing labs are unprofitable for a variety of reasons. The top reasons are poor reimbursement from insurance plans and patients.
[34]
Invitae Completes Sale of Reproductive Health Assets to Natera
Jan 22, 2024 · The value of the transaction is up to $52.5 million, including cash, milestone payments and litigation credits. Natera has hired Invitae ...
[35]
Natera Acquires Reproductive Health Assets from Invitae
Jan 22, 2024 · Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments.
[36]
Invitae Enters into Agreement with Labcorp for Sale of Business
Apr 24, 2024 · Labcorp will acquire substantially all of the Company's assets on a going concern basis for $239 million in cash consideration, plus other non-cash ...Missing: 2025 | Show results with:2025
[37]
Labcorp to acquire Invitae's assets for $239M | MedTech Dive
Apr 25, 2024 · Labcorp has been selected as the winning bidder in the bankruptcy court-supervised sale of medical genetics company Invitae. The laboratory ...
[38]
Invitae Corporation, et al. - Kurtzman Carson Consultants
Invitae filed for Chapter 11 bankruptcy on Feb 13, 2024. The confirmation order was on Aug 2, 2024, and the effective date was Aug 7, 2024.Court Docket · Sale Related Documents · Plan and Disclosure Statement
[39]
With new CEO, Invitae lays off more than 1,000 employees, slims ...
Jul 20, 2022 · Overseen by a newly appointed CEO, genetic testing company Invitae will lay off more than 1000 employees as part of a year-long ...<|separator|>
[40]
Invitae sells reproductive health business to Natera, cuts 238 jobs
Jan 24, 2024 · Jan 24, 2024 ... The company has focused on cancer test offerings, in particular, which made the sale of certain of its reproductive health assets ...
[41]
Invitae Genetic Health Screen (167 Gene) - Innermost Healthcare
About the Invitae Genetic Health Screen. Our most comprehensive proactive health test which analyses more than 167 genes related to inherited cancers, cardiac ...
[42]
Invitae closes a $40M Series E to go global with genetic testing
Dec 10, 2013 · Genomic Health spun off Invitae in February 2012. Redmile Group, Genesys Capital and Casdin Capital are also named in the release, along with ...Missing: spin- | Show results with:spin-
[43]
Invitae announces introduction of exome testing
Mar 30, 2017 · Exome testing analyzes up to 20,000 genes using NGS to help diagnose genetic disorders, especially when the gene is unknown, and aids in ...Missing: whole | Show results with:whole
[44]
Pacific Biosciences and Invitae to Develop Ultra-High-Throughput ...
Jan 13, 2021 · New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care.
[45]
Invitae expands work with Alnylam Pharmaceuticals to provide ...
Oct 29, 2018 · Invitae-sponsored testing programs help lower barriers to obtaining diagnostic genetic information for patients and clinicians. Sponsors provide ...
[46]
Invitae Launches Detect Programs to Make it Easier for Patients to ...
Jul 24, 2019 · Research has shown no-charge testing programs result in earlier diagnosis and treatment. Enrollment is now open for Detect programs in four ...
[47]
Invitae, Epic Sign Deal to Integrate Genetic Test Results Into EMR ...
Mar 21, 2023 · Invitae said on Tuesday that it has signed an agreement to provide access to its genetic test results directly through Epic's Aura specialty diagnostics suite.Missing: electronic records
[48]
ACOG and SMFM guidelines for prenatal diagnosis: Is karyotyping ...
Jan 9, 2018 · The CombiSNP Prenatal microarray is composed of 851,622 SNP probes with a median spatial resolution of 1 Kb within gene-rich regions and 5 Kb ...
[49]
Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering ...
Feb 12, 2019 · NIPS is used to screen pregnancies for chromosomal abnormalities as early as 10 weeks gestation and is also the earliest test that can predict ...
[50]
Everything You Need to Know: Non-Invasive Prenatal Screening
Nov 3, 2019 · Watch this short video to learn about non-invasive prenatal screening (NIPS) ... Our mission is to improve health and improve lives. Company. About · Careers ...
[51]
Invitae Detect Program - SADS Foundation
Invitae is offering the Detect Cardiomyopathy and Arrhythmia Program, which is a no-charge genetic testing and counseling program for individuals suspected ...
[52]
Invitae eMERGE Panel - Clinical Genetic Test - GTR - NCBI - NIH
Clinical Genetic Test offered by Labcorp Genetics (formerly Invitae) for conditions (59): Hypercholesterolemia, autosomal dominant, type B; ...
[53]
Invitae - eMERGE study
Invitae is a clinical affiliate within eMERGE and will conduct genetic testing for up to 20,000 adult patients using a custom panel of 16 genes known to ...Missing: 59- | Show results with:59-
[54]
Invitae announces new leadership structure to drive global growth
Jan 9, 2017 · subsidiary of Genomic Health led by Dr. Scott. Prior to that, he served as chief operating officer at Navigenics, one of the early personal ...Missing: formation | Show results with:formation<|control11|><|separator|>
[55]
Sean Emerson George - Science/Technology is a decade ahead of ...
Invitae Graphic. Co-Founder and CEO. Invitae. Jan 2010 - Jul 2022 12 years 7 months. San Francisco Bay Area. Navigenics Graphic. COO. Navigenics. Jan 2007 - Dec ...
[56]
Invitae Announces Leadership Transition
Jul 18, 2022 · Invitae Announces Leadership Transition: COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors.Missing: 2017-2023 | Show results with:2017-2023
[57]
Invitae Replaces CEO, Plans Reorganization with Narrower Focus
Jul 19, 2022 · Invitae announced that it replaced company co-founder and CEO Sean George with Kenneth D. Knight who has served as COO since 2020.Missing: team changes
[58]
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
Oct 19, 2023 · Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, MD, as chief operating ...Missing: composition | Show results with:composition<|separator|>
[59]
Invitae Announces Appointment of Finance Veteran Ana Schrank as ...
Sep 25, 2023 · Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial ...Missing: composition | Show results with:composition
[60]
Invitae Announces Leadership Transition - PR Newswire
Jul 18, 2022 · COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors. Co-Founder and former CEO Randy Scott returns ...Missing: 2017-2023 | Show results with:2017-2023
[61]
Invitae Corporation: Governance, Directors and Executives ...
Former Officers and Directors: Invitae Corporation ; Patricia E. Dumond. Comptroller/Controller/Auditor, 2013-08-31, - ; Sean George. Director/Board Member, 2022- ...
[62]
Invitae Appoints William H. Osborne to its Board of Directors
Jan 30, 2023 · William H. Osborne has been appointed to its board of directors and will also serve on its audit committee, effective January 26, 2023.Missing: diversity | Show results with:diversity
[63]
Oops, this publication was not found.
**Summary of Diversity, Equity, Inclusion, and Leadership Demographics (2023 ESG Report, Invitae):**
[64]
Invitae sets IPO pricing - - Global Corporate Venturing
Feb 12, 2015 · Invitae was spun out of Genomic in 2012 and has raised $207m in funding, most recently closing a series F round of $140m in October 2014. The ...Missing: pre- | Show results with:pre-
[65]
Precision M&A: Invitae Eyes Growth in Personalized Cancer Tests ...
Jun 22, 2020 · ArcherDx has agreed to be acquired by Invitae for up-to-approximately $1.4 billion just two weeks after filing for a $100 million initial ...
[66]
Invitae (NVTA) - Revenue - Companies Market Cap
In 2022 the company made a revenue of $0.51 Billion USD an increase over the revenue in the year 2021 that were of $0.46 Billion USD. The revenue is the total ...
[67]
Invitae gets court approval for five-month bankruptcy sale | Reuters
Feb 15, 2024 · Invitae reported a $1.3 billion net loss for the first nine months of 2023. Reporting by Dietrich Knauth; Editing by Leslie Adler. Our ...
[68]
Invitae Corporation - SEC.gov
We have granted the underwriters an option for a period of 30 days to purchase up to 952,500 additional shares of common stock.
[69]
Invitae (NVTA) - Stock price history - Companies Market Cap
Stock price history for Invitae (NVTA). Highest end of day price: $57.40 USD on 2020-12-10. Lowest end of day price: $0.01800 USD on 2024-02-08.
[70]
NYSE to Commence Delisting Proceedings Against Invitae ...
Feb 6, 2024 · NYSE Regulation has determined that the Company's common stock is no longer suitable for listing based on “abnormally low” price levels, ...
[71]
Invitae sponsored testing programs: Accessible genetics
Invitae partners with biopharma companies on sponsored, no-charge testing programs to provide access to patients who meet certain eligibility criteria.Missing: 2018 | Show results with:2018